Biotech Stocks Facing FDA Decision In September

Airbnb says employees can work from home until August 2021

Airbnb said Wednesday its employees could choose to work remotely through the end of August 2021, even if some of its offices reopened as COVID-19 restrictions ease.

The company said it would provide a $300 stipend for home office equipment, with an additional $200 to cover ergonomic equipment.

Airbnb said its employees will also have the option to temporarily relocate to states and countries where the company is set up to support them.

US guests were increasingly using its platform to support remote working and temporary relocations, Airbnb said.

The volume of reviews by US guests mentioning “remote working” or “work remotely” since the start of the pandemic has nearly tripled from the same period last year, according to the home rental company.

Airbnb last week filed confidentially for an initial public offering with US regulators, underscoring a rebound in parts of the travel industry, battered this year by the pandemic.

Share this article:

British crabs at risk after colony of aggressive Japanese rivals found in Dorset

BRITISH crabs are at risk from aggressive Japanese rivals, experts warn.

The Asian shore crab, which has already invaded Europe and the eastern US coast, has been found in Essex and Kent.

Now a second colony has been spotted in Weymouth, Dorset.

Dr Paul Clark, a researcher at the Natural History Museum, told The Sun: “This Asian shore crab will out-compete our native shore crabs for shellfish.

“It could lead to a fall in population.”

The species can travel on the side of boats and was first discovered in Britain in 2014.

Females produce up to 50,000 eggs at a time and can have several broods per year.

Once hatched into larvae they can be fully grown in a month and cause trouble for the native shoreline crab species as they overwhelm the habitat.

Brown crabs, found further out at sea, will not be affected.

GOT a story? RING The Sun on 0207 782 4104 or WHATSAPP on 07423720250 or EMAIL

Homes evacuated after ‘large diesel train’ catches fire near Llanelli

Police are evacuating homes in Llangennech, close to Llanelli in Wales, due to a train fire.

Three of the train’s carriages are on fire, according to the local fire service.

A 800m evacuation zone has been put in place around the “large diesel train”, with roads being closed in the local area.

Llangennech County Councillor Gary Jones said that a “major incident” had been declared.

The public is being asked to avoid the area.

Trump Virus Funds for Private Schools Blocked by Second Judge

The Trump administration’s move to steer more pandemic relief money to private schools from a $13 billion education fund was blocked by a second federal judge.

Wednesday’s order by a San Francisco judge follows a preliminary injunction issued last week by a Seattle judge. Both concluded that changes in early Julyto CARES Act emergency funding issued by the administration illegally take money away from disadvantaged public schools to give to private schools with more resources and less need.

Read More: Trump’s Virus Funding Boost for Private Schools Is Blocked

Republican National Convention Day Three: live updates

2020 Republican National Convention, day three

The Republican National Convention's third day got underway on Wednesday. Speakers include South Dakota Gov. Kristi Noem, White House Press Secretary Kayleigh McEnany, Former Amb. Richard Grenell and Vice President Mike Pence.

Follow below on Fox News' live blog. Mobile users click here.

Biotech Stocks Facing FDA Decision In September

As we near the end of another month, it’s time to take a look at some of the news stories that made headlines on the regulatory front.

Roche’s Evrysdi secured FDA approval to treat patients two months of age and older with spinal muscular atrophy on August 7, becoming the first oral treatment for this disease. Evrysdi is the third FDA-approved medication for spinal muscular atrophy after Biogen’s Spinraza and Novartis’ Zolgensma.

The FDA gave speedy approval to NS Pharma’s Viltepso for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping on August 12. Viltepso is the third DMD drug to be greenlighted – the other two are Exondys 51, approved in September 2016, and Vyondys 53, approved in December 2019, both developed by Sarepta Therapeutics.

On August 17, Roche’s Enspryng received the official stamp of approval from the FDA for neuromyelitis optica spectrum disorder, a rare disease affecting optic nerves and spinal cord. Enspryng is the third approved treatment for this disorder. Viela Bio’s Uplizna and Alexion Pharmaceuticals’ Soliris are also approved to treat NMOSD.

So far this year, 36 novel drugs have passed muster with the FDA compared to 26 during the same period (Jan- Aug) in 2019.

Let’s take a look at the companies that await a ruling from the FDA in September.